Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)
For Trade and Medical Media Only Enrolment completed in Phase III ReSPECT study in prophylaxis of fungal infections in adult patients undergoing allogeneic blood and marrow transplant Topline results from ReSPECT study expected by mid-2026 CAMBRIDGE, England
(Financial Post, 2025-10-10T10:30:50Z)